Restart Life Sciences Corp.
NMLSF
$0.06
$0.0111.07%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -20.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -20.80K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -20.80K |
| SG&A Expenses | 899.50K | 865.20K | 813.50K | 452.70K | 390.10K |
| Depreciation & Amortization | 1.30K | 1.40K | 1.50K | 1.60K | 1.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 904.40K | 870.20K | 818.60K | 454.80K | 392.80K |
| Operating Income | -904.40K | -870.20K | -818.60K | -454.80K | -413.60K |
| Income Before Tax | -870.70K | -380.60K | -299.70K | 163.70K | 9.60K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.87 | -0.38 | -0.30 | 0.16 | 0.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -870.70K | -380.60K | -299.70K | 163.70K | 9.60K |
| EBIT | -904.40K | -870.20K | -818.60K | -454.80K | -413.60K |
| EBITDA | -902.90K | -868.60K | -816.90K | -453.10K | -411.70K |
| EPS Basic | -0.03 | 0.00 | 0.00 | 0.01 | 0.00 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.03 | -0.02 | -0.02 |
| EPS Diluted | -0.04 | -0.01 | -0.01 | 0.00 | -0.01 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 112.88M | 91.82M | 73.04M | 61.12M | 59.16M |
| Average Diluted Shares Outstanding | 114.71M | 94.14M | 75.36M | 63.44M | 59.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |